- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01579838
An Open Label Study of the Effects of Eculizumab in CD59 Deficiency
Study Overview
Detailed Description
It has been shown in some scientific studies that lack of CD59 in the context of the disease paroxysmal nocturnal hemoglobinuria (PNH)leads to chronic hemolysis. The investigators have identified patients wirh CD59 deficiency that suffers from chronic hemolysis and demyelinating disease. It was shown that complement terminal pathway can cause cause inflammation in nervous system. Complement can greatly increase the immune attack in the nerves. Eculizumab has already been shown to be effective in a rare blood disorder known as PNH. Attacks of PNH are also mediated through complement. Therefore, the investigators of this study are investigating whether by 'turning off' complement in CD59 deficiency, further attacks of hemolysis and nerve injury can be avoided.
The primary (most important) objectives of this study are to determine:
Whether Eculizumab ameliorate the neurological condition documented in the last month before treatment and whether it reduces the relapse frequency in patients with relapsing chronic inflammatory demyilinating polyneuropathy. The number of attacks during the one year treatment period will be compared to the number of attacks that occurred prior to initiation of eculizumab treatment. For patients with more than 2 year disease duration, the average number of attacks in the preceding 2 years will be calculated. For patients with less than 2 years disease duration the number of attacks in the preceding year will be used.
Whether Eculizumab reduces chronic hemolysis as judged by LDH levels, and haptoglobin, and level of hemoglobin. the same for corticosteroids and or I.V. IgG consumption before and after treatment with eculizumab.
The safety profile of eculizumab in patients with CD59 deficiency will be determined by parents report evry other week, documentation of clinic referral and hospitalizations. The number of participants with advers events will be determined.
The secondary objectives are to determine:
Whether eculizumab maintains or improves limbs motion, function and quality of life as measured by a variety of established disability scales like the modified SF36 and like a questionaire developed for this age group. The investigators will also assess the severity of an individual attack and the degree of recovery.
How the drug behaves in the patient's blood by measuring the presence of membrane attack complex on neutrophils and red blood cells.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Dror Mevorach, MD
- Email: mevorachd@hadassah.org.il
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Recruiting
- Hadassah Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CD59 deficiency
Exclusion Criteria:
- recent exposure to meningococcal infections
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Eculizumab
Eculizumab will be administrated according to known protocols.
|
PNH and or atypical TTP classical protocols
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whether Eculizumab reduces chronic hemolysis
Time Frame: 8 months
|
The primary objectives of this study are to determine: Whether Eculizumab reduces chronic hemolysis as judged by LDH levels, and haptoglobin, and level of hemoglobin. |
8 months
|
Steroid and iv IgG cumulative dosage
Time Frame: 8 months
|
Cumulative steroid and IgG dosage before and after treatment
|
8 months
|
Safety.
Time Frame: 8 months
|
Whether the subjects develop known or possible related side effect to the treatment.
The number of participants that develop adverse effects will be determined.
reports from parents will be taken avery other week and documented clini or hospital visits will be included.
|
8 months
|
Whether Eculizumab ameliorates the neurological status compared to one month before treatment
Time Frame: 8 months
|
The neurological status in the last month prior to treatment will be determined followed by neurological staus examination every two weeks.
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whether eculizumab maintains or improves limbs motion
Time Frame: 8 months
|
Whether there is a neurological amelioration
|
8 months
|
function and quality of life as measured by a variety of established disability scales.
Time Frame: 8 months
|
we will be using evry other week parents report of his clinical condition.
We will use modified SF36 and local questionairre.
|
8 months
|
The severity of an individual attack and the degree of recovery.
Time Frame: 8 months
|
8 months
|
|
Levels of membrane attack complex
Time Frame: 8 months
|
This will be measured using flow cytometry for the presence of membrane attack complex on neutrophild and res blood cells.
|
8 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dror Mevorach, MD, HMO
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD59-Mevorach-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hemolysis
-
Hospices Civils de LyonCompletedChronic HemolysisFrance
-
Guy's and St Thomas' NHS Foundation TrustUniversity of OxfordNot yet recruitingHemolysis Neonatal
-
National Institutes of Health Clinical Center (CC)CompletedIsoagglutinin-Mediated Hemolysis | Probiotic ToxicityUnited States
-
Hanyang UniversityCompletedChronic Kidney Diseases | Hemolysis
-
Cedars-Sinai Medical CenterNot yet recruitingAcute Decompensated Heart Failure | Hemolysis IntravascularUnited States
-
CHU de ReimsUnknownProspective Studies | Chronic Hemolysis | VKA | Anticoagulants / Administration & Dosage | Coated Materials | Biocompatible | Heparin / Administration & Dosage | Membranes Artificial | Renal Dialysis / Methods | Renal Insufficiency / TherapyFrance
-
Universidad Politecnica de MadridUniversidad Europea de Madrid; Fundación Renal Iñigo Alvarez De ToledoCompleted
-
Massachusetts General HospitalSpina, Stefano, M.D., Massachusetts General Hospital; Marrazzo, Francesco,... and other collaboratorsRecruitingCardiovascular Diseases | Endothelial Dysfunction | Cardiovascular Risk Factor | Hemolysis IntravascularUnited States
-
Johns Hopkins UniversityTerminatedEnd Stage Renal Disease | Hemolysis | Arteriovenous GraftUnited States
-
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion...Leiden University Medical CenterCompleted
Clinical Trials on Eculizumab
-
Samsung Bioepis Co., Ltd.CompletedParoxysmal Nocturnal HemoglobinuriaKorea, Republic of, Taiwan, Malaysia, Thailand, Romania, India, Mexico, Ukraine
-
AlexionCompletedAtypical Hemolytic Uremic SyndromeCanada, United Kingdom, France, Germany, Netherlands, Sweden, Italy
-
Alexion PharmaceuticalsCompletedHemoglobinuria, ParoxysmalUnited States, Australia, Belgium, Canada, Germany, Italy, United Kingdom, France, Ireland, Netherlands, Sweden, Switzerland
-
Nantes University HospitalCompletedAtypical Hemolytic Uremic SyndromeFrance
-
AlexionApproved for marketingHemoglobinuria, ParoxysmalUnited States
-
AlexionCompletedAllergic AsthmaCanada
-
Alexion PharmaceuticalsTerminatedMyasthenia GravisUnited States, Canada, United Kingdom
-
Alexion PharmaceuticalsCompletedShiga-like Toxin-producing Escherichia ColiGermany
-
Alexion PharmaceuticalsCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum DisorderHong Kong, Korea, Republic of, United States, Croatia, Australia, Canada, Malaysia, Japan, Italy, Turkey, Spain, Taiwan, Argentina, Colombia, Czechia, Denmark, Germany, Russian Federation, Thailand, United Kingdom
-
Alexion PharmaceuticalsNo longer availableCOVID-19 | Pneumonia, Viral | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)United States, France